SCHEMBL15914767

SCHEMBL15914767

O=S(=O)(NC[C@@H](O)CO)c1ccccc1Br

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 1/20 0.51
▸ RECQL P46063 1/20 0.49
▸ POLB P06746 3/20 0.48
▸ ALDH1A1 P00352 2/20 0.46
▸ ALOX5AP P20292 2/20 0.44
▸ FEN1 P39748 2/20 0.44
▸ PLCG1 P19174 1/20 0.43
▸ SLC6A9 P48067 3/20 0.43
▸ MAPT P10636 2/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA4 P22748 1/20 0.42
▸ CA6 P23280 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15915137 1.00 GBA1 (0.51) GBA1RECQLPOLBALDH1A1ALOX5AP
SCHEMBL15914770 1.00 GBA1 (0.51) GBA1RECQLPOLBALDH1A1ALOX5AP
SCHEMBL15915636 0.83 RECQL (0.54) GBA1RECQLPOLBALOX5APFEN1
SCHEMBL15915633 0.83 RECQL (0.54) GBA1RECQLPOLBALOX5APFEN1
SCHEMBL15915901 0.83 RECQL (0.54) GBA1RECQLPOLBALOX5APFEN1
SCHEMBL2861010 0.81 GBA1 (0.55) GBA1ALDH1A1ALOX5APFEN1SLC6A9
SCHEMBL15918283 0.80 POLB (0.48) GBA1RECQLPOLBALDH1A1ALOX5AP
SCHEMBL15917204 0.80 POLB (0.48) GBA1RECQLPOLBALDH1A1ALOX5AP
SCHEMBL15917203 0.80 POLB (0.48) GBA1RECQLPOLBALDH1A1ALOX5AP
SCHEMBL2227866 0.79 RECQL (0.56) RECQLPOLBALDH1A1ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3495359-A1 FLAP MODULATORS Janssen Pharmaceutica NV (BE) 2019-06-12 — — EP disclosed
EP-3070085-B1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-01-09 — — EP disclosed
EP-3070085-B1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-01-09 — — EP disclosed
EP-2951170-B1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-10-24 — — EP disclosed
US-9884878-B2 FLAP modulators JANSSEN PHARMACEUTICA NV (BE) 2018-02-06 — — US disclosed
US-9884878-B2 FLAP modulators JANSSEN PHARMACEUTICA NV (BE) 2018-02-06 — — US disclosed
US-9884878-B2 FLAP modulators JANSSEN PHARMACEUTICA NV (BE) 2018-02-06 — — US disclosed
US-9745328-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2017-08-29 — — US disclosed
US-9745328-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2017-08-29 — — US disclosed
US-9745328-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2017-08-29 — — US disclosed
US-20150376212-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-12-31 — — US disclosed
US-20150259357-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-09-17 — — US disclosed
US-20150259357-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-09-17 — — US disclosed
US-20150259357-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-09-17 — — US disclosed
US-9079866-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2015-07-14 — — US disclosed
US-9079866-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2015-07-14 — — US disclosed
US-9079866-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2015-07-14 — — US disclosed
US-20140221311-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 — — US disclosed
US-20140221311-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 — — US disclosed
US-20140221311-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376212-A1 FLAP MODULATORS FEN1, PGF, TBXA2R GBA1 3020/4885RECQL 162/4885POLB 1439/4885
US-20150259357-A1 FLAP MODULATORS PGF, FEN1, TBXA2R GBA1 3595/4885RECQL 254/4885POLB 1233/4885
US-20140221311-A1 FLAP MODULATORS PGF, FEN1, TBXA2R GBA1 3595/4885RECQL 254/4885POLB 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback